Cargando…
High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer
BACKGROUND: Prostate cancer (PC) can be stratified into distinct molecular subtypes based on TMPRSS2-ERG gene fusion status, but its potential prognostic value remains controversial. Likewise, routine clinicopathological features cannot clearly distinguish aggressive from indolent tumors at the time...
Autores principales: | Strand, Siri H., Hoyer, Soren, Lynnerup, Anne-Sofie, Haldrup, Christa, Storebjerg, Tine Maj, Borre, Michael, Orntoft, Torben F., Sorensen, Karina D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608326/ https://www.ncbi.nlm.nih.gov/pubmed/26478752 http://dx.doi.org/10.1186/s13148-015-0146-5 |
Ejemplares similares
-
Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer
por: Storebjerg, Tine Maj, et al.
Publicado: (2018) -
5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors
por: Kristensen, Gitte, et al.
Publicado: (2019) -
RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy
por: Strand, Siri H., et al.
Publicado: (2016) -
Epigenomic analysis of 5-hydroxymethylcytosine (5hmC) reveals novel DNA methylation markers for lung cancers
por: Wang, Zhihui, et al.
Publicado: (2020) -
Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis
por: Nørgaard, Maibritt, et al.
Publicado: (2017)